Eugenie Bouchard Sparks Tennis Debate Over Serena Williams’ GLP-1 Use: “I’m Against Doping”

Former tennis star Eugenie Bouchard has publicly weighed in on the growing conversation about the use of GLP-1 weight-loss medications in professional sports. Her remarks directly address the intersection of modern pharmaceutical advancements and athletic integrity within the professional tennis circuit.

Bouchard asserted that she is fundamentally opposed to doping and believes any substance proven to provide a performance-enhancing benefit should be strictly prohibited. While acknowledging that the scientific community is still researching the comprehensive impact of these specific medications on athletes, she emphasized her unwavering commitment to maintaining a level playing field.

It’s interesting because doping is a huge topic in our sport, especially in tennis. I do think if there’s a performance-enhancing aspect to it, then it should be banned. Like, I’m very against, you know, doping in sports. I really believe in clean sport and so if the science and the research comes out with that then I would fully, you know, support not being able to use it. I do think we’re at a point where it’s still kind of so new and they’re probably just trying to like research it and trying to figure out if it even is, you know, performance-enhancing or not. But yeah, I mean, I just believe in clean sport. That’s definitely my opinion.

Eugenie Bouchard said on Front Office Sports

The commentary specifically highlights the endorsement and open discussion of GLP-1 medications by tennis legend Serena Williams. Williams previously revealed that she utilized the treatment to address weight management struggles and underlying health factors following her active playing career.

View this post on Instagram

A post shared by Front Office Sports (@frontofficesports)

By drawing a firm line between personal health choices and competitive sports governance, Bouchard has reignited discussions regarding how governing bodies should classify metabolic drugs. Her position underscores a broader anxiety among competitors regarding where the boundary lies between therapeutic usage and regulatory oversight.

US Open Regulatory Enforcement and Media Rule Exemptions

Following their opening-round doubles defeat at the US Open, Serena and Venus Williams bypassed mandatory post-match media obligations. Under standard Grand Slam regulations, failing to attend these required press sessions can trigger substantial financial penalties for competing athletes.

The tournament rulebook permits players to skip media commitments only under specific, pre-approved circumstances such as acute illness or physical injury. In this instance, the United States Tennis Association (USTA) was not formally notified of any medical exemptions regarding the sisters’ absence.

Despite the explicit violation of media protocols, tournament organizers ultimately chose not to impose any fines against Serena or Venus. This decision bypassed potential combined financial sanctions reaching up to $100,000, drawing contrasting reactions across the tennis community, given strict past enforcements.

Historically, both sisters have faced monetary penalties for similar infractions at major tournaments. The USTA’s leniency at this year’s event highlights an inconsistent application of standard media rules when high-profile legacy competitors are involved.

Scientific and Regulatory Scrutiny of GLP-1 Medications

Serena Williams opened up about her experience using GLP-1 receptor agonists to manage weight fluctuations and mitigate health risks like diabetes. Her documented weight reduction of roughly 34 pounds over a year brought substantial public visibility to a class of drugs typically prescribed for metabolic regulation.

Anti-doping authorities and sports scientists are currently monitoring how the utilization of these medications intersects with athletic conditioning. Because GLP-1 drugs primarily suppress appetite and influence caloric intake, researchers are evaluating whether rapid weight loss confers unfair physiological advantages or impairs muscle retention.

Presently, GLP-1 medications are not explicitly prohibited under standard tennis anti-doping codes. However, figures such as Eugenie Bouchard argue that if ongoing empirical research shows that these compounds enhance athletic performance or recovery, formal restrictions must be implemented.

The ongoing debate reflects a broader regulatory challenge for sports administrators as they navigate modern pharmacology. As athletes increasingly incorporate metabolic treatments into their routines, anti-doping agencies face mounting pressure to establish definitive guidelines for the future of clean competition.

ALSO READ: Aryna Sabalenka Admits It’s Tough for Her to ‘Disconnect’ From No.1 Battle at US Open